1. Search Result
Search Result
Results for "

prostate specific antigen (PSA)

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

2

Natural
Products

2

Recombinant Proteins

3

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P5990

    PSMA Cancer
    Prostate Specific Antigen Substrate is a prostate specific antigen (PSA) fluorescent substrate. Prostate Specific Antigen Substrate can be used for detect enzymatic activity of PSA .
    Prostate Specific Antigen Substrate
  • HY-12759
    CARM1-IN-1
    3 Publications Verification

    Histone Methyltransferase Cancer
    CARM1-IN-1 (compound 7g) is a highly potent and selective inhibitor of CARM1 (IC50=8.6 μM, CARM1/PABP1), with low inhibitory activity against PRMT1 and SET7 (IC50 >667 μM). CARM1-IN-1 inhibits the methylation activity of CARM1 and the methylation levels of different substrates, such as PABP1, CA150, SmB, and H3. CARM1-IN-1 also inhibits the promoter activity of prostate-specific antigen (PSA) without significant cytotoxicity .
    CARM1-IN-1
  • HY-12759A
    CARM1-IN-1 hydrochloride
    3 Publications Verification

    Histone Methyltransferase Cancer
    CARM1-IN-1 (compound 7g) hydrochloride is a highly potent and selective inhibitor of CARM1 (IC50=8.6 μM, CARM1/PABP1), with low inhibitory activity against PRMT1 and SET7 (IC50 >667 μM). CARM1-IN-1 hydrochloride inhibits the methylation activity of CARM1 and the methylation levels of different substrates, such as PABP1, CA150, SmB, and H3. CARM1-IN-1 hydrochloride also inhibits the promoter activity of prostate-specific antigen (PSA) without significant cytotoxicity .
    CARM1-IN-1 hydrochloride
  • HY-N8850

    Others Cancer
    Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC50 value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .
    Angelol G
  • HY-P1813

    PSA-Peptide

    Prostaglandin Receptor Cancer
    PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments .
    PSA1 (141-150)
  • HY-N8856

    Others Others
    Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .
    Angelol M
  • HY-162779

    PSMA Elastase Others
    CDD-3290 (Compound 20) is a prostate-specific antigen (PSA) inhibitor with a Ki value of 216 nM. CDD-3290 also inhibits α-chymotrypsin and elastase .
    CDD-3290
  • HY-P99554

    PRX-302

    PSMA Cancer
    Topsalysin is a PSA-activated protoxin, a pore-forming protein (synthetic proaerolysin) fusion protein with human prostate-specific antigen. Topsalysin has tumor suppression effect in mice modle .
    Topsalysin
  • HY-174391

    Androgen Receptor Apoptosis Cancer
    AR antagonist 15 is an orally active androgen receptor (AR) antagonist with the IC50 of 97 nM for ART787A. AR antagonist 15 disrupts AR nuclear translocation, hinders AR homodimerization, and suppresses transcription of AR-regulated genes by competitive binding to the ligand binding pocket. AR antagonist 15 can significantly lower the prostate-specific antigen (PSA) level. AR antagonist 15 induces apoptosis by reducing the expression of apoptosis pathway related proteins. AR antagonist 15 can be used for the research of prostate cancer.
    AR antagonist 15
  • HY-403733B

    Androgen Receptor Prostaglandin Receptor Cancer
    (+)-JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR) that inhibits AR nuclear localization and transcriptional activity in the absence of androgen. (+)-JJ-450 is less active than (-)-JJ-450 (HY-403733A) in inhibiting prostate-specific antigen (PSA) expression in LN95 cells, possibly because (+)-JJ-450 targets the ligand binding domain (LBD) of AR. (+)-JJ-450 inhibits the transcriptional activity of AR and its splice variants (e.g., ARv7) by promoting the degradation of unliganded AR in the nucleus and reducing the binding of AR to androgen response elements (AREs). (+)-JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to enzalutamide (MDV3100) (HY-70003) .
    (+)-JJ-450

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: